Back to Search
Start Over
SUPERCILLIARY MADAROSIS IN AN INDIAN MALE WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH DASATINIB - A CASE REPORT
- Source :
- Indian Journal of Case Reports. 2:75-78
- Publication Year :
- 2016
- Publisher :
- Mansa STM Publishers, 2016.
-
Abstract
- Dasatinib, a second generation multi-target tyrosine kinase inhibitor (TKI) is active against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases. While skin hypopigmentation is a well recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib. We report a rare case of diffuse cutaneous hypopigmentation and bilateral supercilliary madarosis induced by dasatinib. A 51 year-old Indian male with no co-morbidities and with history of chronic myelogenous leukaemia with complex variant of Philadelphia translocation and E 225 V mutation in P loop domain of bcr-abl transcript who was initiated on imatinib followed by dasatinib as a part of treatment. After 5 months of treatment with dasatinib, he developed supercilliary madarosis bilaterally. Cutaneous side effects may adversely affect patient’s quality of life and, therefore, require prompt attention to prevent long-term complications or suboptimal outcomes due to poor compliance.
- Subjects :
- Oncology
medicine.medical_specialty
medicine.drug_class
business.industry
Madarosis
Imatinib
medicine.disease
Tyrosine-kinase inhibitor
Dasatinib
Endocrinology
hemic and lymphatic diseases
Internal medicine
medicine
medicine.symptom
business
Tyrosine kinase
Chronic myelogenous leukemia
medicine.drug
Proto-oncogene tyrosine-protein kinase Src
Hypopigmentation
Subjects
Details
- ISSN :
- 24541303 and 2454129X
- Volume :
- 2
- Database :
- OpenAIRE
- Journal :
- Indian Journal of Case Reports
- Accession number :
- edsair.doi...........7c20d5c5e57a0a87b98aa17b37e8dc58